Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
Businesswire·2026-01-22 12:45
Core Viewpoint - Takeda has announced the U.S. availability of GAMMAGARD LIQUID ERC, a new liquid immunoglobulin therapy for individuals aged two years and older with primary immunodeficiency, which is approved as a replacement therapy [1] Group 1: Product Details - GAMMAGARD LIQUID ERC is an immune globulin infusion with a low immunoglobulin A (IgA) content of less than or equal to 2 µg/mL in a 10% solution [1] - The product does not require reconstitution, making it convenient for patients [1]